Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. United States/
    2. Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma

    Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma

    December 10, 2022
    December 10, 2022

    Download the PDF